SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Thoracic Oncology Consultation — Jesse Owens — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Jesse Owens |
|---|
| Date of birth | 1913-09-12 |
|---|
| Identifiers | MRN HR-ML042-SYN-TD; SSN (made up) 000-42-8319 |
|---|
| Document date | 1979-05-26 |
|---|
| Author | Ngozi Halvorsen-Pierce, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
Lung-RADS 4X nodule on a first low-dose screening CT in a 65-year-old man who smokes a pack a day (35 pack-years): a solid, spiculated 2.9 cm left upper lobe nodule with an enlarged 1.6 cm left hilar node. PET-CT and brain MRI are booked this week and EBUS staging after that. Please see him within two weeks to review the results with him and plan treatment if this is cancer. [S]
Urgency: Urgent, within two weeks. [S]
Questions for the consultant:
- Is this lung cancer, and what is its stage? Which lymph node stations should be sampled, and is more staging needed?
- Can it be removed, and what treatment do you recommend, in what order?
- Which biomarkers must be back before treatment starts, and do any of them change the plan?
- Is he fit for lung resection, and what preparation would help?
- How should his smoking be treated alongside cancer care, and does stopping now still matter?
- What monitoring should primary care share during and after treatment, and does he need palliative care?
History of Present Illness
Mr. Owens, 65, is seen at the request of Dr. Whitfield-Arroyo 15 days after his first low-dose screening CT showed a Lung-RADS 4X left upper lobe nodule and an enlarged left hilar node. Since then he has had PET-CT, brain MRI, endobronchial ultrasound with node sampling, and pulmonary function tests this morning, and our thoracic tumor board reviewed him five days ago. He has a long-standing morning cough and no other symptoms. He smokes a pack a day, 35 pack-years, and says he is ready to stop. He is fully active (ECOG 0). [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- James Cleveland (J.C.) Owens was born on September 12, 1913, in Oakville, Alabama, the youngest of the children of Henry and Mary Emma Owens, who were sharecroppers. The Ohio State University Libraries give ten children; contemporary newspaper accounts and his own account give nine. [D]
- As a child in Alabama he worked in the fields with his family. At about 7 he had pneumonia and nearly died; a brother and a sister died during the same epidemic. He later described himself as a sickly, emaciated, poverty-stricken child, and said that his parents knew the family had to leave to survive. In the early 1920s the family moved north to Cleveland, following an older sister who had written home about jobs there. [D]
- In Cleveland a teacher misheard his initials J.C. and called him Jesse, and the name stuck. Coached by Charles Riley from junior high school, he won the long jump, set a world record in the 220-yard dash and tied the world record in the 100-yard dash at the National Interscholastic Championship in 1933. [D]
- At the Ohio State University, which he entered in 1933, he was barred from the men's dormitory because of his race, lived in a boarding house with other African American students, and could not eat in the restaurants along High Street. He worked as a freight elevator operator. At the Big Ten championships in May 1935 he set world records in the 220-yard dash, the 220-yard low hurdles and the long jump. [D]
- At the 1936 Olympic Games in Berlin he won four gold medals, in the 100 meters, the 200 meters, the long jump and the 4 x 100-meter relay, and he was given a ticker-tape parade in New York on his return. [D]
- The offers that followed the Games did not become steady work. He earned money racing against horses and local sprinters, and said that Black athletes were not allowed in any professional sport then. A dry-cleaning business he founded in 1938 went into debt, and he filed for personal bankruptcy in 1939. He owed taxes on his income after the Games, and decades later was in trouble with the Internal Revenue Service again for failing to file returns. He later worked through public relations firms, as a speaker, and with youth organizations. [D]
- He met Minnie Ruth Solomon at Fairmount Junior High School in Cleveland in 1930; they married and had three daughters. In the early 1970s, with their children grown, they moved from Chicago, their home of more than 20 years, to the Phoenix area of Arizona. Ruth Owens died in 2001. [D]
- The Ohio State University awarded him an honorary doctorate of athletic arts, and in 1976 he received the Presidential Medal of Freedom. He served on the board of directors of the U.S. Olympic Committee from 1973. [D]
- He smoked cigarettes for decades: at his death newspapers described him as a pack-a-day smoker for the past 35 years, and his doctors said he had smoked about a pack a day. The Ohio State University Libraries call him a lifetime smoker. [D]
2 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Varenicline 0.5 mg oral tablet: one tablet daily for three days, then one tablet twice daily for four days (starting week), with a quit date on day 8 | 0.5 mg daily on days 1 to 3, then 0.5 mg twice daily on days 4 to 7 | Oral route | 1979-05-26 to 1979-06-01 | completed | S |
| Folic acid 1 mg oral tablet, one tablet daily from one week before the first pemetrexed dose until three weeks after the last | One tablet daily | Oral route | 1979-05-26 to 1979-08-05 | completed | S |
| Cyanocobalamin (vitamin B12) 1000 mcg intramuscular injection, one dose a week before the first pemetrexed dose (repeat every nine weeks while on pemetrexed) | 1000 mcg once; a second dose was not due before pemetrexed ended | Intramuscular route | 1979-05-26 to 1979-05-26 | completed | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Solid, spiculated 2.9 cm nodule in the left upper lobe with an enlarged (1.6 cm) left hilar lymph node on today's low-dose screening CT, Lung-RADS 4X (very suspicious); no symptoms of lung cancer. PET-CT, tissue diagnosis and thoracic oncology review booked | resolved | confirmed |
R91.1 | S — Synthetic presenting screening finding in a long-term smoker. Superseded by the diagnosis at the second visit. |
| Adenocarcinoma of the left upper lobe of the lung, cT1c N1 M0, stage IIB (AJCC 8th edition), resectable: 2.9 cm primary with a positive left interlobar (11L) node on EBUS; mediastinal nodes 4R, 4L and 7 negative; no metastases on PET-CT or brain MRI. PD-L1 tumor proportion score 40 percent (22C3); KRAS G12C mutation; no EGFR, ALK, ROS1, BRAF, MET exon 14, RET, NTRK or HER2 alteration | active | confirmed |
C34.12 | S — Synthetic histology, stage and biomarkers linked to his documented adenocarcinoma of the left lung; in the modern episode it is found by screening while still resectable. |
| Nicotine dependence, cigarettes: a pack a day for 35 years (35 pack-years); smokes his first cigarette within 30 minutes of waking; two attempts to stop, each lasting a few weeks without medicine | active | confirmed |
F17.210 | S — Synthetic modern entry linked to his documented smoking; superseded at the visit after surgery by nicotine dependence in early remission. |
Physical Exam
Vital signs recorded on 1979-05-26; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Well and upright; weight 76.6 kg; blood pressure 130/80, pulse 80; oxygen saturation 95 percent; ECOG 0 |
| Lymph nodes | No supraclavicular or cervical nodes |
| Respiratory | Scattered rhonchi that clear with a cough; no wheeze |
| Extremities | No clubbing |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1979-05-26 | Hemoglobin [Mass/volume] in Blood | 14.9 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1979-05-26 | Leukocytes [#/volume] in Blood by Automated count | 8.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1979-05-26 | Neutrophils [#/volume] in Blood by Automated count | 5.2 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 1979-05-26 | Platelets [#/volume] in Blood by Automated count | 258 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1979-05-26 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1979-05-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1974)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1979-05-26 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 1979-05-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 7-55 U/L | Normal | S |
| 1979-05-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-48 U/L | Normal | S |
| 1979-05-26 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1979-05-26 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1979-05-26 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1979-05-26 | Cortisol [Mass/volume] in Serum or Plasma | 13.8 | ug/dL | Morning (8 a.m.) reference interval | Normal | S |
| 1979-05-26 | FEV1 | 2.71 | L | Lower limit of normal for his age and height (GLI 1965) | Normal | S |
| 1979-05-26 | FEV1 measured/predicted | 86 | % | >=80% | Normal | S |
| 1979-05-26 | FEV1/FVC | 0.73 | {ratio} | Below 0.70 after bronchodilator indicates airflow obstruction | Normal | S |
| 1979-05-26 | Diffusion capacity.carbon monoxide | 23.6 | mL/min/mm[Hg] | Lower limit of normal for his age and height; predicted 27.4 | Normal | S |
| 1979-05-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | | | S |
| 1979-05-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | | | S |
Assessment
- Adenocarcinoma of the left upper lobe, cT1c N1 M0, stage IIB, resectable (C34.12). Question 1: this is lung adenocarcinoma, stage IIB (AJCC 8th edition): a 2.9 cm primary with a positive interlobar node and negative mediastinal stations on systematic EBUS sampling (4R, 4L and 7 plus 10L), as ACCP guidance advises when a hilar node is positive; PET-CT and brain MRI complete the staging, and no mediastinoscopy is needed. Question 2: it is resectable by lobectomy. Because EGFR and ALK are negative, the tumor board recommends three cycles of nivolumab with carboplatin and pemetrexed before surgery (CheckMate 816), which improved event-free survival and the rate of pathologic complete response over surgery alone without making surgery less feasible, then thoracoscopic left upper lobectomy with systematic node dissection. Question 3: EGFR and ALK had to be excluded first, because targeted therapy, not chemoimmunotherapy, would be preferred around surgery if either were present; PD-L1 of 40 percent supports immunotherapy. KRAS G12C does not change treatment for resectable disease but makes sotorasib or adagrasib options if it ever recurs. [S]
- Nicotine dependence, cigarettes (F17.210). Question 5: stopping smoking now lowers the risk of complications after surgery and the risk of recurrence and second cancers, and improves survival; it is part of his cancer treatment. Varenicline with counseling is the most effective approach. [S]
Data reviewed: Dr. Whitfield-Arroyo's intake note and results. Screening CT: 2.9 cm solid spiculated nodule in the apicoposterior left upper lobe; 1.6 cm left hilar node; mild upper-lobe emphysema; coronary calcification. FDG PET-CT: avid nodule (SUVmax 9.8) and avid 11L node (SUVmax 6.1); no mediastinal, supraclavicular or distant uptake. Brain MRI: no metastases. EBUS with systematic sampling: adenocarcinoma in 11L, TTF-1 positive; 4R, 4L, 7 and 10L negative with adequate lymphocytes. PD-L1 (22C3) 40 percent. Tissue sequencing with concordant plasma testing: KRAS G12C; STK11 and KEAP1 wild type; no EGFR, ALK, ROS1, BRAF V600E, MET exon 14, RET, NTRK or HER2 alteration. Pulmonary function today: FEV1 2.71 L (86 percent predicted), FEV1/FVC 0.73, DLCO 86 percent predicted. Today's blood count, creatinine 1.0 mg/dL, liver tests, TSH 1.9 and morning cortisol 13.8 are normal. [S]
Plan of Treatment
- Three cycles of nivolumab 360 mg with carboplatin AUC 5 and pemetrexed 500 mg/m2 every three weeks, starting in about a week; folic acid and vitamin B12 first; dexamethasone around each pemetrexed dose; hepatitis B, hepatitis C and HIV tests before cycle 1. [S]
- Restaging CT of the chest and upper abdomen after cycle 3, then thoracoscopic left upper lobectomy with systematic mediastinal and hilar node dissection about five weeks after the last cycle. [S]
- Question 4: he is fit for lobectomy. Predicted postoperative FEV1 and DLCO are both about 63 percent, above 60 percent, so no exercise test is needed (ACCP). Prehabilitation in a pulmonary rehabilitation program during chemotherapy, and rehabilitation again after surgery. [S]
- Immune-related adverse event monitoring before each cycle: blood count, TSH, free T4, liver tests, creatinine and glucose, with morning cortisol at baseline and before each infusion; a written list of warning symptoms (new cough or breathlessness, diarrhea, rash, yellowing, severe tiredness or headache) and the 24-hour oncology line. [S]
- Varenicline from today with a quit date on the day of cycle 1, the quitline, and tobacco review at every visit. [S]
- After surgery, decide on further treatment from the pathology: with a major pathologic response and negative nodes, surveillance is reasonable, since this regimen was given before surgery only; then chest CT every six months for two to three years and yearly low-dose CT afterwards, with no routine PET-CT, brain MRI or tumor markers. [S]
- Question 6: primary care to share symptom, mood and distress screening, tobacco support, vaccinations (pneumococcal vaccine before treatment) and the preventive care due at his age. Specialist palliative care is not needed now for a cancer treated with curative intent and causing no symptoms; we will refer if needs arise. [S]
- Discussed with Dr. Whitfield-Arroyo the same day and presented at the thoracic tumor board with surgery, radiology and pathology. The images, the stage and the aim of cure were explained to Mr. Owens in plain words, with written next steps and a nurse navigator's number; he chose to start chemoimmunotherapy and to stop smoking on the day of cycle 1. He decides who else receives this note. Because Black patients with early lung cancer have less often been offered surgery, the navigator tracks each date against the plan. [S]
- Follow-up: Cycle 1 in eight days; oncology review before each cycle; thoracic surgery review after cycle 2; restaging after cycle 3; Dr. Whitfield-Arroyo continues primary care and shares the monitoring. [S]